Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease

por Burisch, Johan, Zhang, He, Choong, Casey Kar-Chan, Nelson, David, Naegeli, April, Gibble, Theresa, Goetz, Iris, Egeberg, Alexander
Publicado 2021

Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States

por Gibble, Theresa Hunter, Naegeli, April N., Grabner, Michael, Isenberg, Keith, Shan, Mingyang, Teng, Chia-Chen, Curtis, Jeffrey R.
Publicado 2023

Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement...

por Dubinsky, Marla C, Clemow, David B, Hunter Gibble, Theresa, Li, Xingyuan, Vermeire, Severine, Hisamatsu, Tadakazu, Travis, Simon P L
Publicado 2022

Rectal Urgency Among Patients With Ulcerative Colitis or Crohn’s Disease: Analyses from a Global Survey

por Ha, Christina, Naegeli, April N, Lukanova, Rina, Shan, Mingyang, Wild, Rosie, Hennessy, Fritha, Jyothi Kommoju, Uma, Potts Bleakman, Alison, Hunter Gibble, Theresa
Publicado 2023

Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions

por Dubinsky, Marla, Bleakman, Alison Potts, Panaccione, Remo, Hibi, Toshifumi, Schreiber, Stefan, Rubin, David, Dignass, Axel, Redondo, Isabel, Gibble, Theresa Hunter, Kayhan, Cem, Travis, Simon
Publicado 2023

Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies

por Sands, Bruce E, Feagan, Brian G, Hunter Gibble, Theresa, Traxler, Kristina A, Morris, Nathan, Eastman, William J, Schreiber, Stefan, Jairath, Vipul, Long, Millie D, Armuzzi, Alessandro
Publicado 2023